AstraZeneca’s Monalizumab Phase 3 Data Due H2 2026 After Revenue Shift
AstraZeneca’s monalizumab Pacific 9 Phase 3 trial is set for an H2 2026 data readout, while project management shift led to a significant drop in Innate Pharma’s collaboration revenue. Early anti-tumor activity of IPH 4,502 in urothelial cancer and FDA clearance for lacutamab’s Telemax 3 trial reinforce pipeline synergies as IPHA holds $44.8 million cash into Q3 2026.
1. Monalizumab Phase 3 Pacific 9 Trial
The Pacific 9 trial, part of the AstraZeneca–Innate Pharma collaboration, will deliver pivotal Phase 3 monalizumab data in the second half of 2026. The interim Matisse analysis will cover the first 40 patients, with efficacy and safety endpoints designed to validate the checkpoint inhibitor’s benefit in lung cancer.
2. Collaboration Revenue Shift
Innate Pharma reported a significant decline in collaboration revenue from the monalizumab program after project management responsibilities transferred fully to AstraZeneca. This change underscores AstraZeneca’s expanded operational role and may alter near-term partnership accounting and R&D cost allocation.
3. Pipeline Synergies and Funding Outlook
Early signs of anti-tumor activity for IPH 4,502 in heavily pretreated urothelial cancer and FDA clearance for lacutamab’s Phase 3 Telemax 3 trial present complementary assets for AstraZeneca’s oncology portfolio. Innate Pharma’s $44.8 million cash position supports operations through Q3 2026, setting the stage for funding discussions on joint development programmes.